- Abstract viewed - 772 times
- PDF downloaded - 331 times
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
© Medicine and Pharmacy Reports, 2023
Edvina Elena Pirvu
Genetics Department, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania; Medical Oncology Department, “Coltea” Clinical Hospital “, Bucharest, Romania
Genetics Department, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
Physiology Department, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania; Medical Oncology Clinic, “Elias” University Emergency Hospital, Bucharest, Romania
Ștefania Andreea Toma
Medical Oncology Department, Ponderas Academic Hospital, Bucharest, Romania
How to Cite
The impact of RAS mutation on the treatment strategy of colorectal cancer
Vol 96 No 1 (2023)
Kirsten rat sarcoma (KRAS) is the most frequently mutated oncogene in colorectal cancer, being present in 30% of patients with localized disease and in almost half of the patients that develop metastatic disease. While the development of chemotherapy doublets and targeted therapy have improved survival in recent years, KRAS mutation still has a controversial role regarding its prognostic and predictive value both in the adjuvant and in the metastatic setting. The impact of KRAS mutation on treatment strategy remains to be better defined. The development of new KRAS inhibitors promising new treatment options is on the horizon.